XML 50 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended
Nov. 06, 2022
Nov. 06, 2022
Oct. 07, 2022
Jun. 17, 2022
Jun. 30, 2021
May 11, 2021
Apr. 09, 2021
Aug. 12, 2020
Aug. 01, 2020
Jul. 15, 2020
Jul. 14, 2020
Jun. 30, 2022
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Shares outstanding                             3,882,292   3,894,792
Stock option vested exercisable term                             15 months    
Stock based compensation                             $ 276,980 $ 339,672  
Number of fully vested option exercisable 100,000 100,000                         2,913,542   2,819,792
Share based compensation vesting rights, percentage                             12.50%    
Total deferred compensation expense for outstanding value of unvested stock options                             $ 605,000    
Intrinsic value of exercisable but unexercised in-the-money stock options                             $ 56,500    
Fair market value, per share                             $ 0.83    
Outstanding stock options to acquire shares of common stock not vested                             968,750    
Director [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options description                         the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock, exercisable for a period of five years at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $316,700 ($0.6334 per share), which is being charged to operations ratably from July 1, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $23,394 with respect to these stock options        
Stock options are exercisable price per share $ 0.5025 $ 0.5025                   $ 0.74 $ 0.74        
Stock price per share $ 2.00 $ 2.00                   $ 0.6334 $ 0.6334        
Stock based compensation                             $ 23,394    
Number of fully vested option exercisable 200,000 200,000                   500,000 500,000        
Purchase of shares                       100,000          
Five Non Officer Directors [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options description         the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock, exercisable for a period of five years at an exercise price of $3.03 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,421,095 ($2.84225 per share), which is being charged to operations ratably from July 1, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $105,123 and $175,205, respectively, with respect to these stock options                        
Stock options are exercisable price per share         $ 3.03                 $ 3.03      
Fair value of stock options $ 43,264                       $ 316,700 $ 1,421,095      
Stock price per share $ 0.4326 $ 0.4326     $ 2.84225                 $ 2.84225      
Stock based compensation                             105,123 175,205  
Number of fully vested option exercisable         100,000                 100,000      
Non Officer Directors [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Number of fully vested option exercisable         500,000                 500,000      
BasvanderBaan [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options description       the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Baan was granted stock options to purchase 250,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $0.74 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($0.6341 per share), of which $79,263 was attributable to the portion of the stock options fully vested on June 17, 2022 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from June 17, 2022 through June 30, 2024. During the three months ended March 31, 2023, the Company recorded a total charge to general and administrative costs in the consolidated statement of operations of $9,588 with respect to these stock options                          
Stock options are exercisable price per share       $ 0.74                          
Fair value of stock options       $ 158,525                          
Stock price per share       $ 0.6341                          
Stock based compensation                             9,588    
Number of fully vested option exercisable       250,000                          
Stock options granted to purchase common stock, issued       $ 79,263                          
Four Officers [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock option vested exercisable term   5 years                              
Fair value of stock options $ 262,560                                
Stock price per share $ 0.3282 $ 0.3282                              
Stock based compensation                             16,172    
Number of fully vested option exercisable 800,000 800,000                              
Share based compensation vesting rights, percentage 25.00%                                
Stock options granted to purchase common stock, issued 800,000                                
Eric J. Forman [Member] | Employment Agreement [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options granted to purchase common stock, issued                   58,333              
Stock options description                   On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted stock options to purchase 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,710 and $24,710, respectively, with respect to these stock options              
Stock option vested exercisable term                   5 years              
Stock options are exercisable price per share                   $ 7.14              
Fair value of stock options                   $ 400,855              
Stock price per share                   $ 6.8718              
Stock options fully vested amount, fair value               $ 100,214                  
Stock based compensation                             24,710 24,710  
Dr. James Miser [Member] | Employment Agreement [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options granted to purchase common stock, issued                 83,334                
Stock options description                 Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase 83,334 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 1, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the portion of the stock options fully vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $35,300 and $35,300, respectively, with respect to these stock options                
Stock options are exercisable price per share                 $ 7.14                
Fair value of stock options                 $ 572,650                
Stock price per share                 $ 6.8718                
Stock options fully vested amount, fair value                 $ 143,163                
Stock based compensation                             35,300 35,300  
Robert N. Weingarten [Member] | Employment Agreement [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options granted to purchase common stock, issued               58,333                  
Stock options description               On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with the final 25% vesting on August 12, 2023, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,710 and $24,710, respectively, with respect to these stock options                  
Stock options are exercisable price per share               $ 7.14                  
Fair value of stock options               $ 400,855                  
Stock price per share               $ 6.8718                  
Stock options fully vested amount, fair value               $ 100,214                  
Stock based compensation                             24,710 24,710  
Dr Winson SzeChun Ho [Member] | Director [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options description             the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by a former director’s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted stock options to purchase 250,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $3.20 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $753,611 ($3.0144 per share), of which $376,800 was attributable to the portion of the stock options fully vested on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was being charged to operations ratably from April 9, 2021 through June 30, 2023. However, vesting of these stock options terminated on October 30, 2022, the date that Mr. Schwartzberg died. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $0 and $41,764, respectively, with respect to these stock options                    
Stock options are exercisable price per share             $ 3.20                    
Fair value of stock options             $ 753,611                    
Stock price per share             $ 3.0144                    
Stock options fully vested amount, fair value             $ 376,800                    
Stock based compensation                             0 41,764  
Number of fully vested option exercisable             250,000                    
Ms.Regina Brown [Member] | Director [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Stock options description           the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted stock options to purchase 250,000 shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $2.80 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per share), of which $329,188 was attributable to the portion of the stock options fully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2023 and 2022, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $37,983 and $37,983, respectively, with respect to these stock options                      
Stock options are exercisable price per share           $ 2.80                      
Fair value of stock options           $ 658,363                      
Stock price per share           $ 2.6335                      
Stock options fully vested amount, fair value           $ 329,188                      
Stock based compensation                             $ 37,983 $ 37,983  
Number of fully vested option exercisable           250,000                      
2020 Stock Incentive Plan [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Common shares avaliable for issuable     1,800,000                            
Stock options granted to purchase common stock, issued     4,133,333                            
Shares outstanding                             2,603,125    
Shares were available for issuance                             1,530,208    
2020 Stock Incentive Plan [Member] | Maximum [Member]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                                  
Number of restricted stock issued                     2,333,333